News

Research shows THC, the main psychoactive compound in cannabis, can cause false memories, source memory confusion, and impaired prospective memory. A double-blind trial in the Journal of Psychopharmacology found that even 20mg of THC disrupts verbal, visuospatial, and temporal order memory while increasing false memory susceptibility. INSERM research reveals THC impairs working memory via mitochondrial CB1 receptors. A 2024 AMA fMRI study found low-to-moderate dose medical cannabis did not significantly reduce cognition over one year. Adolescent THC use poses higher risks of lasting memory deficits.

U.S. CBD industry faces a pivotal evidence battle in federal court over Medicare inclusion, mirroring Europe’s regulatory failures on safety data gaps.

This May Day, we do not celebrate any single person. We salute everyone: those who bent their backs, stayed up through the night, shed sweat, and worked silently. Every seed remembers. Every machine remembers. Every product remembers.

Labor is not one day’s effort. It is a team’s daily reality. Happy May Day, dear partners.

Thailand’s cannabis industry is undergoing a high-stakes transformation from a loosely regulated market to a strict medical framework. Following 2025 reforms that banned recreational sales and limited cannabis flowers to prescription-only use, over 7,000 dispensaries have closed, and demand has shifted toward illicit channels. Despite current market contraction—valued at $1.7 billion in 2025—revenue is projected to hit$7.1 billion by 2030 (33.0% CAGR). However, severe price inversion (indoor flower at $0.50–$1.00/g), gatekeeper-driven export bottlenecks, oversupply, and the rise of mega-plantations and extract commoditization are destabilizing the sector. By 2026–2027, survival depends on disciplined, vertically integrated growers with direct global distribution, strong branding, and pharmaceutical-grade compliance, as community-centered values risk being eroded by industrial-scale capital.

A recent joint study by Virginia Tech and Kyung Hee University shows that industrial hemp waste can be upcycled into high-performance, fully bio-based molded fiber composites for sustainable packaging. By using underutilized hemp stalks, starch, and cellulose nanofibers, researchers developed an eco-friendly alternative to traditional molded pulp—avoiding toxic PFAS and petroleum-based plastics. The optimized composite offers improved mechanical strength and biodegradability, turning low-value agricultural byproducts into a revenue stream. This breakthrough supports whole-plant utilization and positions hemp waste as a scalable, sustainable resource for the packaging industry.

In a fragmented market, resilience—not size—defines success. By 2026, global cannabis and hemp supply chains are shaped by upstream enablers (genetics, terpenes, papers), midstream innovators (infusion tech, post-harvest standardization, biomanufacturing), and compliance-led distributors (EU-GMP logistics, medical hubs, cross-border finance). From True Terpenes and Azuca to Tilray, Canopy, and Cansativa, industry leaders prioritize adaptability, regulatory navigation, and multi-regional infrastructure. Hemp remains both opportunity and volatility. The future belongs to operators who treat regulation as a design parameter and build redundant, scalable, and auditable supply chains.

This study reveals the neural mechanism of THC-induced anxiety: activation of CB1 receptors in the ACC→DMS brain circuit suppresses neurotransmission, driving avoidance and anxiety-like behaviors. High-dose THC triggers aversion via this pathway, while specific CB1 knockout blocks the effect. Published in Nature Communications by the Medical College of Wisconsin.

On April 18, President Trump signed an executive order directing the FDA to fast-track psychedelic therapies for veterans with PTSD and traumatic brain injuries. The policy funds ibogaine research—a Schedule I substance—and signals a major federal shift on controlled substances. With Joe Rogan and RFK Jr. backing the move, advocates say the order could drive cannabis rescheduling and unlock rigorous PTSD studies, offering new hope for veteran mental health and suicide prevention.

A recent study published in the Journal of Medical Cannabis and Cannabinoids found that cannabinoid therapy—alone or combined with chemotherapy—may help manage prostate cancer. The prospective observational study of 90 patients showed that cannabis use was associated with faster prostate-specific antigen (PSA) decline, higher rates of tumor remission or shrinkage on PET/CT scans, and significant improvements in pain relief, emotional well-being, self-care, and daily activities compared to chemotherapy alone. No harm was observed. Researchers call for further randomized controlled trials to confirm the adjuvant role of cannabinoids in prostate cancer treatment. Keywords: medical cannabis, prostate cancer, cannabinoids, PSA, PET/CT, pain management, oncology.